NO2625199T3 - - Google Patents

Info

Publication number
NO2625199T3
NO2625199T3 NO11764764A NO11764764A NO2625199T3 NO 2625199 T3 NO2625199 T3 NO 2625199T3 NO 11764764 A NO11764764 A NO 11764764A NO 11764764 A NO11764764 A NO 11764764A NO 2625199 T3 NO2625199 T3 NO 2625199T3
Authority
NO
Norway
Application number
NO11764764A
Other languages
Norwegian (no)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44759699&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO2625199(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of NO2625199T3 publication Critical patent/NO2625199T3/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NO11764764A 2010-10-08 2011-10-07 NO2625199T3 (sv)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US39138810P 2010-10-08 2010-10-08
PCT/EP2011/067522 WO2012045848A1 (en) 2010-10-08 2011-10-07 Methods of treating psoriasis using il-17 antagonists

Publications (1)

Publication Number Publication Date
NO2625199T3 true NO2625199T3 (sv) 2018-04-21

Family

ID=44759699

Family Applications (1)

Application Number Title Priority Date Filing Date
NO11764764A NO2625199T3 (sv) 2010-10-08 2011-10-07

Country Status (27)

Country Link
US (6) US9717791B2 (sv)
EP (4) EP3299390A1 (sv)
JP (2) JP5537740B2 (sv)
KR (3) KR20150018595A (sv)
CN (2) CN103154031A (sv)
AU (1) AU2011311482B2 (sv)
BR (1) BR112013008501A2 (sv)
CA (1) CA2813900C (sv)
CL (1) CL2013000930A1 (sv)
CY (1) CY1119942T1 (sv)
DK (1) DK2625199T3 (sv)
ES (1) ES2660770T3 (sv)
HK (1) HK1247932A1 (sv)
HR (1) HRP20180301T1 (sv)
HU (1) HUE038334T2 (sv)
IL (1) IL225310A (sv)
LT (1) LT2625199T (sv)
MA (1) MA34646B1 (sv)
MX (1) MX356279B (sv)
NO (1) NO2625199T3 (sv)
PL (1) PL2625199T3 (sv)
PT (1) PT2625199T (sv)
RU (2) RU2591083C2 (sv)
SG (1) SG188979A1 (sv)
SI (1) SI2625199T1 (sv)
TW (2) TWI548419B (sv)
WO (1) WO2012045848A1 (sv)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7833527B2 (en) 2006-10-02 2010-11-16 Amgen Inc. Methods of treating psoriasis using IL-17 Receptor A antibodies
JO3244B1 (ar) 2009-10-26 2018-03-08 Amgen Inc بروتينات ربط مستضادات il – 23 البشرية
SI3295957T1 (sl) 2010-01-15 2020-02-28 Kirin-Amgen, Inc. Formulacija protitelesa proti IL-17RA in terapevtski režim za zdravljenje luskavice
SG185354A1 (en) 2010-05-20 2012-12-28 Ablynx Nv Biological materials related to her3
UA117218C2 (uk) 2011-05-05 2018-07-10 Мерк Патент Гмбх Поліпептид, спрямований проти il-17a, il-17f та/або il17-a/f
WO2013077907A1 (en) * 2011-11-21 2013-05-30 Novartis Ag Methods of treating psoriatic arthritis (psa) using il-17 antagonists and psa response or non- response alleles
WO2014149425A1 (en) * 2013-03-15 2014-09-25 Amgen Inc. Methods for treating psoriasis using an anti-il-23 antibody
CN105307675A (zh) * 2013-03-15 2016-02-03 美国安进公司 使用抗il23抗体治疗克罗恩氏病的方法
WO2015022656A1 (en) 2013-08-15 2015-02-19 Novartis Ag Methods of treating generalized pustular psoriasis (gpp) using il-17 antagonists
WO2015099167A1 (ja) * 2013-12-27 2015-07-02 国立大学法人大阪大学 Ｉｌ－１７ａを標的とするワクチン
RU2577228C2 (ru) * 2014-03-14 2016-03-10 Закрытое Акционерное Общество "Биокад" Анти-il-17-антитела, способ их получения и способ применения
KR102530900B1 (ko) * 2014-03-31 2023-05-12 암젠 케이-에이, 인크. 손발톱 및 두피 건선의 치료 방법
CA3198322A1 (en) 2014-05-15 2015-11-19 Rani Therapeutics, Llc Pharmaceutical compositions and methods for fabrication of solid masses comprising polypeptides and/or proteins
US11548940B2 (en) * 2014-05-15 2023-01-10 Rani Therapeutics, Llc Anti-interleukin antibody preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US20170298136A1 (en) * 2014-08-26 2017-10-19 Kirin-Amgen, Inc. Method for treating psoriasis patient which received anti-tnf-alpha antibody therapy
BR112017003332A2 (pt) * 2014-09-10 2017-11-28 Novartis Ag uso de antagonistas de il-17 para inibir a progressão de dano estrutural em pacientes com artrite psoriásica
AR103173A1 (es) * 2014-12-22 2017-04-19 Novarits Ag Productos farmacéuticos y composiciones líquidas estables de anticuerpos il-17
AR103172A1 (es) * 2014-12-22 2017-04-19 Novartis Ag Reducción selectiva de residuos de cisteina en anticuerpos il-17
US20180036404A1 (en) 2015-03-02 2018-02-08 180 Therapeutics Lp Method of treating a localized fibrotic disorder using a tnf receptor 2 antagonist
EP3167892A1 (en) 2015-11-10 2017-05-17 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for preventing or treating imflammatory bowel diseases
CN108350068A (zh) * 2015-10-27 2018-07-31 Ucb生物制药私人有限公司 使用抗-il-17a/f抗体的治疗方法
US20190194311A1 (en) * 2016-07-19 2019-06-27 Novartis Ag Methods of treating new-onset plaque type psoriasis using il-17 antagonists
JP2019505516A (ja) * 2016-11-28 2019-02-28 ノバルティス アーゲー インターロイキン−１７（ｉｌ−１７）アンタゴニストを使用してざ瘡を治療する方法
WO2018158741A1 (en) * 2017-03-03 2018-09-07 Novartis Ag Psoriasis disease modification following long-term treatment with an il-17 antagonist
CA3073597A1 (en) * 2017-08-23 2019-02-28 Eli Lilly And Company Treatment of genital psoriasis
TWI808397B (zh) * 2018-09-11 2023-07-11 美商美國禮來大藥廠 治療牛皮癬之方法
CN114127108A (zh) 2019-07-30 2022-03-01 江苏恒瑞医药股份有限公司 Il-17拮抗剂治疗自身免疫疾病的方法
TW202246329A (zh) * 2021-03-03 2022-12-01 大陸商蘇州盛迪亞生物醫藥有限公司 抗il-17抗體治療自體免疫性疾病和炎症的方法
WO2023186174A1 (en) * 2022-04-01 2023-10-05 Zai Lab (Shanghai) Co., Ltd. Topical formulation comprising an il-17a binding molecule and uses thereof
CN116593718B (zh) * 2023-07-18 2023-09-15 军科正源（北京）药物研究有限责任公司 用于检测司库奇尤单抗抗药性抗体的试剂

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9422306D0 (en) * 1994-11-04 1994-12-21 Sandoz Ltd Organic compounds
US6093745A (en) * 1997-11-25 2000-07-25 Psorx, L.L.C. Methods and composition for treating skin proliferative diseases
WO2002032374A2 (en) * 2000-10-18 2002-04-25 Immunex Corporation Methods for treating il-18 mediated disorders
US20090280065A1 (en) * 2006-04-10 2009-11-12 Willian Mary K Uses and Compositions for Treatment of Psoriasis
TWI439284B (zh) * 2004-04-09 2014-06-01 Abbvie Biotechnology Ltd 用於治療ＴＮＦα相關失調症之多重可變劑量療法
GB0417487D0 (en) * 2004-08-05 2004-09-08 Novartis Ag Organic compound
DK1933869T3 (da) * 2005-09-01 2010-03-01 Schering Corp Anvendelse af IL-23- og IL-17-antagonister til behandling af autoimmun øjenbetændelsessygdom
EP3366702B1 (en) * 2005-12-13 2023-08-09 Eli Lilly And Company Anti-il-17 antibodies
TW200815469A (en) 2006-06-23 2008-04-01 Astrazeneca Ab Compounds
RU2367429C2 (ru) 2007-01-30 2009-09-20 Государственное учреждение Научно-исследовательский институт клинической иммунологии СО РАМН Способ лечения псориаза
EP2152318A4 (en) * 2007-06-01 2011-12-07 Abbott Biotech Ltd COMPOSITIONS AND USES FOR THE TREATMENT OF PSORIASIS AND CROHN'S DISEASE
RU2341272C1 (ru) * 2007-10-22 2008-12-20 Левон Никитович Мкртчян Средство для неспецифической иммунотерапии
CN102617735B (zh) * 2008-09-29 2015-09-09 罗氏格黎卡特股份公司 针对人il17的抗体及其应用

Also Published As

Publication number Publication date
AU2011311482A1 (en) 2013-04-04
JP5537740B2 (ja) 2014-07-02
SI2625199T1 (en) 2018-03-30
EP4137514A1 (en) 2023-02-22
TWI548419B (zh) 2016-09-11
KR20150018595A (ko) 2015-02-23
SG188979A1 (en) 2013-05-31
US20130202610A1 (en) 2013-08-08
US10583190B2 (en) 2020-03-10
JP2014114288A (ja) 2014-06-26
MX2013003916A (es) 2013-06-03
TW201216984A (en) 2012-05-01
WO2012045848A1 (en) 2012-04-12
ES2660770T3 (es) 2018-03-26
KR20130110179A (ko) 2013-10-08
PT2625199T (pt) 2018-02-28
CL2013000930A1 (es) 2014-03-28
HK1247932A1 (zh) 2018-10-05
CN103154031A (zh) 2013-06-12
US20210162044A1 (en) 2021-06-03
HUE038334T2 (hu) 2018-10-29
IL225310A0 (en) 2013-06-27
IL225310A (en) 2016-10-31
EP3299390A1 (en) 2018-03-28
EP2625199A1 (en) 2013-08-14
DK2625199T3 (en) 2018-02-26
KR20140097566A (ko) 2014-08-06
BR112013008501A2 (pt) 2016-08-16
TW201630625A (zh) 2016-09-01
CA2813900C (en) 2017-01-10
TWI564022B (zh) 2017-01-01
EP3792281A1 (en) 2021-03-17
CN107029234A (zh) 2017-08-11
RU2665954C1 (ru) 2018-09-05
US20210113688A1 (en) 2021-04-22
PL2625199T3 (pl) 2018-04-30
JP2013543501A (ja) 2013-12-05
CA2813900A1 (en) 2012-04-12
RU2591083C2 (ru) 2016-07-10
US20200171147A1 (en) 2020-06-04
MA34646B1 (fr) 2013-11-02
RU2013120957A (ru) 2014-11-20
EP2625199B1 (en) 2017-11-22
US9717791B2 (en) 2017-08-01
US20170304439A1 (en) 2017-10-26
LT2625199T (lt) 2018-03-12
AU2011311482B2 (en) 2014-05-29
HRP20180301T1 (hr) 2018-03-23
KR101620771B1 (ko) 2016-05-12
US20230321231A1 (en) 2023-10-12
MX356279B (es) 2018-05-22
US11534490B2 (en) 2022-12-27
CY1119942T1 (el) 2018-12-12

Similar Documents

Publication Publication Date Title
BR112013013385A2 (sv)
BR112013008959A2 (sv)
BR112012031500A2 (sv)
BR112012029986A2 (sv)
BR112012028408A2 (sv)
BR112012026492A2 (sv)
BR112012024897A2 (sv)
BR112012019354A2 (sv)
BR112012025307A2 (sv)
BR112012002126A2 (sv)
BR112012026946A2 (sv)
BR112012017960A2 (sv)
BR112012025482A2 (sv)
BR112013006400A2 (sv)
BR112012031826A2 (sv)
BR112012025577A2 (sv)
BR112012023249A2 (sv)
BR112012016456A2 (sv)
BR112012027015A2 (sv)
BR112012025308A2 (sv)
BR112012018256A2 (sv)
BR112012027945A2 (sv)
BR112012024872A2 (sv)
BR112012023265A2 (sv)
BR112013010949A2 (sv)